Long-lasting control with erlotinib in advanced non-small cell lung cancer (NSCLC) [0.03%]
厄洛替尼对晚期非小细胞肺癌的长期控制效果
Teresa Guimarães,Ana Castro,Nuno Cortesão et al.
Teresa Guimarães et al.
The authors present a clinical case of a caucasian male patient, 59 years-old, non-smoker, with an advanced non-small cell lung carcinoma (NSCLC), with 3 years of follow-up, received erlotinib for 18 months, after failure of more than one c...
Long survival with erlotinib as second line treatment in non-small cell lung cancer [0.03%]
非小细胞肺癌二线治疗应用厄洛替尼长期生存一例报告
Mariana Sousa,Susana Cavadas,Maria José Moreira et al.
Mariana Sousa et al.
Male, of 69 years old, caucasian, farmer, non smoker, with hypertension, dyslipidemia and past pesticide exposition, without known familiar diseases. In October/2005, he initiated dyspnoea and asthenia for moderate efforts, cough and night ...
Erlotinib in non-small cell lung cancer's second line treatment. Clinical case [0.03%]
厄洛替尼在非小细胞肺癌二线治疗中的应用。临床病例
Mariana Sousa,Susana Cavadas,Maria José Moreira et al.
Mariana Sousa et al.
Male, of 58 years, caucasian, construction worker, non smoker, with depressive syndrome, biliary lithiasis, renal cysts, surgery for benign intestinal polyps and relevant familiar history - aunt with lung cancer and mother with colon cancer...
Maria José Simões,Helena Marques,Elvira Camacho et al.
Maria José Simões et al.
A 75 year old woman was observed at the emergency department with cough, hyperthermia and thoracic pain in October 2004.A pleural effusion was identified and studied. Thorax CT scan evidenced a pleural effusion and thickening in the RSL ant...
Non-small cell lung cancer patients treated with erlotinib - Clinical cases [0.03%]
厄洛替尼治疗的非小细胞肺癌患者 - 临床病例
Jorge Dionísio,Teresa Almodôvar,Dina Matias et al.
Jorge Dionísio et al.
We present four patients with non-small cell lung cancer treated in second and third line with Erlotinib. These are selected patients that obtained a good clinical response. Almost all presented cutaneous side effects. Rev Port Pneumol 2008...
Rui Rolo,Lourdes Iglésias,Lurdes Ferreira et al.
Rui Rolo et al.
Introduction: Erlotinib is an approved treatment for NSCLC locally advanced or with metastases, after failure of initial chemotherapy. The authors present a NSCLC clinical case of great clinical and imaging improvement, w...
Treatment of non-small cell lung cancer, advanced disease, with erlotinib in 2(nd) and 3(rd) lines. Two cases report [0.03%]
厄洛替尼治疗晚期非小细胞肺癌的二线和三线治疗。两例报告
Encarnação Teixeira,Renato Sotto-Mayor,Rita Macedo et al.
Encarnação Teixeira et al.
Agents that inhibit the activity of cell membrane receptor tyrosine kinases, such as the human epidermal growth factor receptor (EGFR) have been an attractive target because EGFR is expressed by 80% of NSCLC. Erlotinib as monotherapy in the...
Erlotinib: An EGFR inhibitor with therapeutic benefit in non-small cell lung cancer [0.03%]
厄洛替尼：一种对非小细胞肺癌具有治疗益处的EGFR抑制剂
Renato Sotto-Mayor
Renato Sotto-Mayor
Treatment of advanced non small cell lung cancer with erlotinib. Two clinical cases [0.03%]
厄洛替尼治疗晚期非小细胞肺癌两例报告
Bárbara Parente,Joana Gomes,Carla Nogueira et al.
Bárbara Parente et al.
Early studies with tirosine kinase inhibitors (TKI), namely Erlotinib and Gefitinib, in patients with non small cell lung cancer (NSCLC), showed that although most patients did not respond radiologically, a small percentage of those patient...
Fernando Barata,Teresa Costa,Ana Figueiredo
Fernando Barata
We report two cases of brain metastases in context of non small cell lung cancer (NSCLC). After having progressed to chemotherapy they received erlotinib 150mg/m2 orally daily, with complete response of brain metastasis and partial response...